Risk of dying with a prolactinoma is not the same for everyone
Original title: Importance of clinical profiling to determine excess mortality in prolactinomas: insights from a large, registry-based cohort.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a look back at patient records, not a test of a new treatment.
The short version
People with a prolactinoma had different odds of dying, depending on their age, sex, and tumor size.
What was studied. Researchers looked at health records for 3,378 adults with a prolactinoma. The records came from a large US registry and covered 2004 to 2022. The team compared how many people died to how many deaths were expected in the general public.
What they found. As a whole group, people with a prolactinoma died somewhat more often than expected. The team then sorted 2,481 patients who had tumor size on file into two groups. One group was 63% of them: younger, mostly women, with small tumors. The other was 37%: older, mostly men, with large tumors. The older group with large tumors had a higher chance of dying. The younger group with small tumors had a lower chance.
What this means, and what it doesn't
What it could mean: Age, sex, and tumor size may shape a person's outlook with this tumor. If you have a prolactinoma, you could ask your doctor which pattern your case looks like. That may help you and your doctor plan how closely to watch it.
What it doesn't mean: This does not mean a prolactinoma will shorten your life. The study only looked back at old records. It cannot show what caused the deaths, and it did not test any treatment. The authors call this an early finding that needs more study. It is not a cure and it does not change care today.
Source: PubMed, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.